Updated results from ALTER-C001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC
机构：[1]Sichuan Canc Hosp, Chengdu, Peoples R China四川省肿瘤医院[2]Southwest Med Univ, Affiliated Hosp, Dept Med Oncol, Luzhou, Peoples R China[3]Chongqing Univ, Three Gorges Hosp, Dept Med Oncol, Chongqing, Peoples R China[4]UESTC, Affiliated Canc Hosp, Sch Med, Dept Med Oncol,Sichuan Canc Hosp & Inst, Chengdu, Peoples R China四川省肿瘤医院[5]Chongqing Univ, Canc Hosp, Gastrointestinal Canc Ctr, Chongqing, Peoples R China
第一作者机构：[1]Sichuan Canc Hosp, Chengdu, Peoples R China
推荐引用方式(GB/T 7714)：
Yan Jin,Han Yunwei,Zhang Li,et al.Updated results from ALTER-C001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC[J].JOURNAL OF CLINICAL ONCOLOGY.2023,41:137-137.doi:10.1200/JCO.2023.41.4_suppl.137.
APA：
Yan, Jin,Han, Yunwei,Zhang, Li,Jin, Yongdong&Sun, Hao.(2023).Updated results from ALTER-C001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC.JOURNAL OF CLINICAL ONCOLOGY,41,
MLA：
Yan, Jin,et al."Updated results from ALTER-C001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC".JOURNAL OF CLINICAL ONCOLOGY 41.(2023):137-137
医学